Baricitinib in the Treatment of Intestinal Behçet's Syndrome

Summary

This study aims to conduct a randomized controlled trial to compare the efficacy and safety of Baricitinib and Adalimumab (ADA) in the treatment of refractory intestinal Behçet's Syndrome (BS). The objective is to demonstrate if Baricitinib is non-inferior to ADA in controlling BS inflammation, reducing BS recurrence， alleviating gastrointestinal symptoms and promoting intestinal mucosal healing.

Timeline

Start

2024-11-08

Primary completion

2027-06-30

Completion

2028-06-30

Drugs

Indications